首页> 外国专利> ANILINOPYRIMIDINES AS HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS

ANILINOPYRIMIDINES AS HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS

机译：苯胺嘧啶作为造血祖细胞激酶1（HPK1）抑制剂

页面导航

摘要
著录项
相似文献

摘要

The invention relates to HPK1 inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: where A, R₁, R₂, R₃, R₄, R₅, R₆, R₁₆, R₁₇, X₁, X₂, X₃, X₄, m, and n are described herein.; embedded image

机译：本发明涉及用于治疗癌症和其他丝氨酸-苏氨酸激酶介导的疾病的HPK 1 抑制剂，其具有下式：其中A，R _{1 ，R _{2 ，R _{3 ，R _{4 ，R _{5 ，R _{6 ，R _{16 ，R _{17 ，X _{1 ，X _{2 ，X _{3 ，X _{4 ，m和n。}}}}}}}}}}}} 展开▼

著录项

公开/公告号US2019382379A1

专利类型

公开/公告日2019-12-19

原文格式PDF

申请/专利权人 ARIAD PHARMACEUTICALS INC.;
展开▼

申请/专利号US201716465073

发明设计人 WEI-SHENG HUANG;YUN ZHANG;WILLMEN YOUNGSAYE;XIAOTIAN ZHU;ERIN GENO;
展开▼

申请日2017-11-29

分类号C07D403/12;C07D401/12;C07D455/04;C07D239/48;C07D405/14;

国家 US

入库时间 2022-08-21 11:24:23

相似文献

专利

外文文献

中文文献

1. 4－氨基－5－氰基－2－苯胺基－嘧啶衍生物和它们作为细胞周期激酶的抑制剂的用途 [P] . 中国专利： CN1231471C . 2005.12.14

2. 4－氨基－5－氰基－2－苯胺基－嘧啶衍生物和它们作为细胞周期激酶的抑制剂的用途 [P] . 中国专利： CN1419548A . 2003-05-21

3. ANILINOPYRIMIDINES AS HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS [P] . 欧洲知识产权局专利： EP3548479A1 . 2019-10-09

机译：苯胺嘧啶作为造血祖细胞激酶1（HPK1）抑制剂

4. ANILINOPYRIMIDINES AS HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS [P] . 世界知识产权组织专利： WO2018102366A1 . 2018-06-07

机译：苯胺嘧啶作为造血祖细胞激酶1（HPK1）抑制剂

5. Anilinopyrimidine AS as hematopoietic precursor kinase 1 (HPK1) inhibitor [P] . 日本专利： JP2020503271A . 2020-01-30

机译： Anilinopyrimidine AS作为造血前体激酶1（HPK1）抑制剂

1. Erratum to “Response of Subcutaneous Xenografts of Endometrial Cancer in Nude Mice to Inhibitors of Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase (MAPK) Pathways: An Effective Therapeutic Strategy for Endometrial Cancer” Journal of Cancer Therapy, 6, 1083-1092 [J] . Ruixia Guo, Xinyan Wang, Ruifang Zhang, 癌症治疗（英文） . 2021,第010期

2. Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies [J] . Si Jingwen, Shi Xiangjun, Sun Shuhao, Cancer Cell . 2020,第4期

3. Hematopoietic progenitor kinase 1 (HPK1) is required for LFA-1-mediated neutrophil recruitment during the acute inflammatory response. [J] . Sascha M Jakob, Robert Pick, Doris Brechtefeld, Blood: The Journal of the American Society of Hematology . 2013,第20期

4. Hematopoietic progenitor kinase 1 (HPK1) is required for LFA-1-mediated neutrophil recruitment during the acute inflammatory response. [J] . Sascha M Jakob, Robert Pick, Doris Brechtefeld, Blood: The Journal of the American Society of Hematology . 2013,第20期

5. A heterogeneous population of mononuclear cells in haematopoietic progenitor cell expansion as an approach to increase output for erythroid maturation [C] . Theun van Veen, Fanrong Pu, Nicholas P. Rhodes, World biomaterials congress . 2012

6. Molecular mechanisms for specific kinase inhibitors and kinase promiscuity towards inhibitors. [D] . Georghiou, George. 2014

7. Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N’-4-(pyrimidin-4-ylamino)phenylurea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily [O] . Valentina Gandin, Alessandro Ferrarese, Martina Dalla Via, -1

8. Activation of the Hematopoietic Progenitor Kinase-1 (HPK1)-dependent, Stress-activated c-Jun N-terminal Kinase (JNK) Pathway by Transforming Growth Factor β (TGF-β)-activated Kinase (TAK1), a Kinase Mediator of TGF β Signal Transduction [O] . Wenfu Wang, Guisheng Zhou, Mickey C.-T. Hu, 1997

1. The combination of epidermal growth factor and glycogen synthase kinase 3 inhibitor support long-term self-renewal of Sca-1 positive hepatic progenitor cells from normal adult mice [J] . Cai-Xia Jin ,Lisa Samuelson ,Cai-Bin Cui . 干细胞探索（英文） . 2013,第3期

2. Bcr-Abl-mediated Raf kinase inhibitor protein suppression promotes chronic myeloid leukemia progenitor cells proliferation [J] . Satoki Nakamura ,Tomohiro Yagyu ,Tomonari Takemura . 干细胞探索（英文） . 2011,第3期

3. Focal adhesion kinase-related non-kinase ameliorates liver fibrosis by inhibiting aerobic glycolysis via the FAK/Ras/c-myc/ENO1 pathway [J] . Tao Huang ,Yuan-Qing-Xiao Li ,Ming-Yu Zhou . 世界胃肠病学杂志:英文版 . 2022,第1期

4. Response of Subcutaneous Xenografts of Endometrial Cancer in Nude Mice to Inhibitors of Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase (MAPK) Pathways: An Effective Therapeutic Strategy for Endometrial Cancer [J] . Ruixia Guo ,Xinyan Wang ,Ruifang Zhang . 癌症治疗（英文） . 2015,第12期

5. 酪氨酸激酶抑制剂—苯基呋咱类NO供体型苯胺嘧啶新衍生物的设计与合成 [C] . 周微 ,董伟兵 . 2009年中国药学大会暨第九届中国药师周 . 2009

6. 造血祖细胞激酶HPK1对非特殊型浸润性乳腺癌生物学特征影响及其分子机制研究 [A] . 王娇娇 . 2017